Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Axol Bioscience
Axol Bioscience
Activities:
Research & Development
Cardiovascular
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Axol Bioscience and Censo Biotechnologies announce merger
Under the terms of the agreement, Axol CEO, Liam Taylor, and the company’s senior leadership team will take over the management of the combined entity
Research & Development
Axol Bioscience launches human iPSC-derived microglia
A reproducible, physiologically relevant cellular model of human microglia for neurodegenerative disease drug discovery and development
Research & Development
Axol Bioscience launch Human iPSC-derived Atrial Cardiomyocytes
A consistent and reproducible model for drug development, toxicity testing and disease modelling applications
Subscribe now